医学
地塞米松
氟辛醇酮
荟萃分析
随机对照试验
植入
系统回顾
相对风险
皮质类固醇
白内障
眼科
内科学
外科
梅德林
置信区间
政治学
法学
作者
Rafael José Vieira,Bernardo Sousa‐Pinto,Luís Figueira
标识
DOI:10.1080/09273948.2020.1787463
摘要
Background/aims To compare different existent implants for noninfectious uveitis.Methods We performed a systematic review of randomized clinical trials (RCTs), searching in five electronic databases and screening reference lists of included studies and relevant reviews. We performed network meta-analysis to compare 0.18 mg fluocinolone acetonide implants, 0.70 mg and 0.35 mg dexamethasone implants, and sham procedures.Results Eight RCTs were included in this systematic review, of which three articles from two studies (n = 358 patients) were included in network meta-analysis. The 0.70 mg dexamethasone implant (at 1.5 months) was associated with better results than the 0.18 mg fluocinolone acetonide implant (at 1 month) at improving vitreous haze grading (RR = 2.96; 95%CI = 1.23–7.07), and with less frequently development of cataracts at 12 (RR = 0.36; 95%CI = 0.17; 0.79) and 36 months (RR = 0.37; 95%CI = 0.20; 0.71).Conclusions In the short term, the 0.70 mg dexamethasone implant is superior at improving vitreous haze, and shows lower risk of cataracts. However, additional RCTs with standardized outcomes are needed.
科研通智能强力驱动
Strongly Powered by AbleSci AI